Aditxt (ADTX) Research & Development (2019 - 2026)
Aditxt (ADTX) recorded quarterly Research & Development of $1.0 million in Q1 2026, up 90.88% quarter-over-quarter from $548556.0 in Q4 2025, and down 13.41% on a YoY basis from $1.2 million in Q1 2025.
Aditxt (ADTX) Research & Development (2019 - 2026) Analysis & Trends
Aditxt's Research & Development history runs 8 years deep, the most recent figure standing at $1.0 million for Q1 2026.
- In Q1 2026, Research & Development fell 13.41% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at $3.0 million (down 23.24% YoY), while the FY2025 annual figure was $3.2 million, down 70.66% from the prior year.
- Research & Development was $1.0 million for Q1 2026 at Aditxt, up from $548556.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $8.1 million in Q1 2024 to a low of $484835.0 in Q2 2023.
- Historically, Research & Development has averaged $1.7 million across 5 years, with a median of $1.2 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 487.03% in 2024, then sank 85.15% in 2025.
- A 5-year view of Research & Development shows it stood at $3.1 million in 2022, then surged by 39.66% to $4.3 million in 2023, then tumbled by 83.83% to $695952.0 in 2024, then fell by 21.18% to $548556.0 in 2025, then jumped by 90.88% to $1.0 million in 2026.
- The last three Research & Development figures came in at $1.0 million (Q1 2026), $548556.0 (Q4 2025), and $672045.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | Aditxt | 2,485.68 | -2.16 Mn | 2,868.00 | 1.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.05 Mn |
| Dec 31, 2025 | 548,556.00 |
| Sep 30, 2025 | 672,045.00 |
| Jun 30, 2025 | 764,327.00 |
| Mar 31, 2025 | 1.21 Mn |
| Dec 31, 2024 | 695,952.00 |
| Sep 30, 2024 | 491,552.00 |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 8.15 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 898,724.00 |
| Jun 30, 2023 | 484,835.00 |
| Mar 31, 2023 | 1.39 Mn |
| Dec 31, 2022 | 3.08 Mn |
| Sep 30, 2022 | 1.57 Mn |
| Jun 30, 2022 | 1.19 Mn |
| Mar 31, 2022 | 1.43 Mn |
| Dec 31, 2021 | 1.70 Mn |
| Sep 30, 2021 | 1.47 Mn |
| Jun 30, 2021 | 932,751.00 |